he HM model hospital It is one of eight hospitals across Spain participating in the program Pharmaceutical company Hipra’s H11 research,the purpose is Evaluating the safety and immune response of Bimervax® COVID-19 vaccine when administered together with seasonal influenza vaccine (one dose in each arm) Adults 65 years or older who are getting their first dose of the mRNA vaccine to protect against coronavirus.Clinical trials authorized by the State Food and Drug Administration Spanish Agency for Medicines and Health Products (Aemps).
The study will be assessed by the Royal Hospital Ethics Committee and Aemps, Cooperation of 300 volunteersHM Modelo de A Coruña explained that during the two-month period, each participant had to go to the hospital three times.
Those who are interested in participating can leave their information at the internal medicine counter of the center, and the center will contact them and evaluate whether their personal information is suitable for participating in Hipra clinical trials.
Selected candidates will be notified a few days before their appointment to receive two vaccines: one for the coronavirus and another for the seasonal influenza vaccine being administered during Galicia’s current vaccination campaign.
Last year, HM Modelo Hospital also participated in a Hipra clinical trial to evaluate the immunogenicity and safety of the Bimervax booster vaccine in people who had previously received two doses of AstraZeneca adenovirus.
The hospital centers involved include four Catalan hospitals: Valladolid Clinic, Royal Model Hospital of A Coruna, Santiago Hospital and Malaga Regional Hospital.